These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 3909539)

  • 1. Determination of free disopyramide plasma concentrations using ultrafiltration and enzyme multiplied immunoassay.
    Raghow G; Meyer MC; Straughn AB
    Ther Drug Monit; 1985; 7(4):466-71. PubMed ID: 3909539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors affecting the binding of disopyramide to serum proteins.
    Shaw LM; Altman R; Thompson BC; Fields L
    Clin Chem; 1985 Apr; 31(4):616-9. PubMed ID: 3884182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of unbound fraction of disopyramide in plasma: a comparison of equilibrium dialysis, ultrafiltration through dialysis membranes and ultrafree anticonvulsant drug filters.
    Norris RL; Ahokas JT; Ravenscroft PJ
    J Pharmacol Methods; 1982 Jan; 7(1):7-14. PubMed ID: 7070107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma protein binding of disopyramide by equilibrium dialysis and ultrafiltration.
    David BM; Tjokrosetio R; Ilett KF
    Ther Drug Monit; 1983; 5(1):81-6. PubMed ID: 6845403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid sample preparation and high performance liquid chromatographic determination of total and unbound serum disopyramide.
    Taylor EH; Nelson D; Taylor RD; Pappas AA
    Ther Drug Monit; 1986; 8(2):219-22. PubMed ID: 3726939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pharmacokinetic and pharmacodynamic effects of varying the free fraction of disopyramide.
    Shaw LM; Doherty JU; Waxman HL; Josephson ME
    Angiology; 1987 Feb; 38(2 Pt 2):192-7. PubMed ID: 3826754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous determination of disopyramide and its mono-N-dealkylated metabolite enantiomers in human plasma and urine by enantioselective high-performance liquid chromatography.
    Takahashi H; Tamura A; Ogata H; Masuhara K
    J Chromatogr; 1990 Aug; 529(2):347-58. PubMed ID: 2229254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of fluorescence immunoassay for total and unbound serum concentrations of disopyramide.
    Lima JJ; Shields BJ; Howell LH; MacKichan JJ
    Ther Drug Monit; 1984; 6(2):203-10. PubMed ID: 6377599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immediate- versus controlled-release disopyramide: importance of saturable binding.
    Davies RF; Siddoway LA; Shaw L; Barbey JT; Roden DM; Woosley RL
    Clin Pharmacol Ther; 1993 Jul; 54(1):16-22. PubMed ID: 8330460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disopyramide: clinical indications, pharmacokinetics and laboratory assessment.
    Taylor EH; Pappas AA
    Ann Clin Lab Sci; 1986; 16(4):289-95. PubMed ID: 2427003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic-pharmacodynamic analysis of unbound disopyramide directly measured in serial plasma samples in man.
    Thibonnier M; Holford NH; Upton RA; Blume CD; Williams RL
    J Pharmacokinet Biopharm; 1984 Dec; 12(6):559-73. PubMed ID: 6398364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disopyramide analysis using REMEDi: comparison with EMIT and conventional high performance liquid chromatographic methods.
    Patel V; McCarthy PT; Flanagan RJ
    Biomed Chromatogr; 1991 Nov; 5(6):269-72. PubMed ID: 1760593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of saturable binding to plasma proteins on the pharmacokinetic properties of disopyramide.
    Giacomini KM; Swezey SE; Turner-Tamiyasu K; Blaschke TF
    J Pharmacokinet Biopharm; 1982 Feb; 10(1):1-14. PubMed ID: 7069575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of a high pressure liquid chromatographic analysis and an enzyme immunoassay technique for quantitation of disopyramide in serum or plasma.
    Bryson SM; Betts A; Summer DJ; Whiting B
    J Clin Hosp Pharm; 1982 Jun; 7(2):119-26. PubMed ID: 7050181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ultrafiltration compared with equilibrium dialysis in the determination of unbound phenytoin in plasma.
    Koike Y; Magnusson A; Steiner E; Rane A; Sjöqvist F
    Ther Drug Monit; 1985; 7(4):461-5. PubMed ID: 3909538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison between two methods for the determination of the total and free (R)- and (S)-disopyramide in plasma using an alpha 1-acid glycoprotein column.
    Enquist M; Hermansson J
    J Chromatogr; 1989 Sep; 494():143-56. PubMed ID: 2584312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction of disopyramide enantiomers for sites on plasma protein.
    Lima JJ
    Life Sci; 1987 Dec; 41(26):2807-13. PubMed ID: 3695808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Applicability of capillary gas liquid chromatography to the measurement of free fraction of disopyramide in human plasma.
    Kapil RP; Axelson JE; Lalka D; Edwards DJ; Kerr CR
    Res Commun Chem Pathol Pharmacol; 1985 Apr; 48(1):153-6. PubMed ID: 3992030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simplified, rapid and inexpensive extraction procedure for a high-performance liquid chromatographic method for determination of disopyramide and its main metabolite mono-N-dealkylated disopyramide in serum.
    Mayer F; Krämer BK; Ress KM; Kühlkamp V; Liebich HM; Risler T; Seipel L
    J Chromatogr; 1991 Dec; 572(1-2):339-45. PubMed ID: 1818071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liquid chromatographic analysis of disopyramide and its mono-N-dealkylated metabolite.
    Lima JJ
    Clin Chem; 1979 Mar; 25(3):405-8. PubMed ID: 262180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.